Green Cath Labs: How Device Reprocessing Cuts Carbon

Sustainability used to be a side project in healthcare. Now it is showing up in board meetings, procurement contracts, and accreditation checklists. Most of the conversation focuses on energy use and recycling programs, but there is a bigger, less-talked-about lever sitting in plain sight: what happens to the single-use devices that cath labs and EP labs run through every single day.

Catheters, sheaths, IVUS probes, and atherectomy devices are labeled "single-use," but a lot of that plastic and hardware is more durable than the label suggests. When those devices are reprocessed through an FDA-regulated program instead of tossed after one case, the environmental math changes in a way that is worth paying attention to.

Healthcare's carbon problem is bigger than most people realize

The U.S. healthcare sector is responsible for roughly 8.5 percent of the country's total greenhouse gas emissions.^[1] Globally, healthcare accounts for around 4.4 percent of emissions, which puts the sector in the same league as some entire industries.^[2] Most of that footprint does not come from hospital buildings or ambulances. It comes from the supply chain: the manufacturing, packaging, and shipping behind everything a facility buys and uses.

Procedure areas carry more than their fair share of this. Operating rooms and cath labs can use up to six times more energy per square foot than the rest of a facility, and they generate over half of a facility's total waste.^[2] If you have ever looked at the size of a case cart after a routine cath procedure, that number probably tracks.

The case for reprocessing, in plain numbers

This is where reprocessing comes in. A growing stack of peer-reviewed life cycle assessments, studies that measure a product's environmental impact from raw material to disposal, have compared new devices against their reprocessed counterparts. The consistent finding is a 40 to 60 percent reduction in greenhouse gas emissions for the reprocessed version, with an average reduction of around 44 percent across the studies.^[3]

Cardiovascular devices show up prominently in this data for a simple reason: they tend to be high cost, high volume, and packed with components like imaging elements, steering mechanisms, and wiring, the kind of parts where manufacturing accounts for a large chunk of a device's total footprint. That is exactly the kind of device where reuse makes the biggest dent.

What this looks like at scale

Individually, one reprocessed catheter is a rounding error on a global emissions chart. But multiply that across thousands of facilities doing this consistently, and the numbers stop being small. In 2024 alone, third-party reprocessors helped facilities across the country avoid more than 113 million pounds of CO2-equivalent emissions, on top of generating over $398 million in savings, according to data from the Association of Medical Device Reprocessors (AMDR) cited in a 2025 National Academy of Medicine report.^[3] For context, that emissions figure is roughly comparable to the emissions from burning nearly 5.8 million gallons of gasoline.^[3]

What this looks like on the ground

National totals are useful, but the individual program numbers make the case even easier to picture. A few examples from published case studies:

What both of these examples have in common is that the savings came from process and consistency, not new equipment or a different way of running procedures. The devices being reprocessed were already in use. The only change was where they went after the case ended.

What the safety record actually shows

This is usually the first question that comes up, and it is a fair one. The FDA has regulated single-use device reprocessing since 2000, and treats reprocessors as manufacturers, holding them to the same validation, testing, and quality requirements as the companies that made the original device.^[3] A 2008 Government Accountability Office review found that the data available at the time did not indicate reprocessed devices posed a higher health risk than new ones, though the report also noted limitations in that data and the difficulty of drawing direct comparisons.^[6] Findings can vary by device type, reprocessing method, and regulatory clearance status, which is exactly why validation and testing requirements are so demanding.

Every device that comes back for reuse goes through cleaning, functional testing, and sterilization before it is cleared to go back into circulation. Devices that do not meet spec are pulled from the process rather than returned to use.

Getting a program off the ground

None of this requires ripping up an existing workflow. The programs that succeed tend to follow a similar pattern:

The bottom line

Reprocessing will not single-handedly solve healthcare's climate footprint, but it is one of the few sustainability moves that is already validated, already regulated, and already sitting in most cath labs' supply closets waiting to be used. The devices do not need to change. The workflow does not need to change. What changes is where a catheter goes once the case is done, and what that one decision adds up to across a year of procedures.